National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 05/30/2008



Purpose of This PDQ Summary






General Information






Cellular Classification and Prognostic Variables






Treatment Option Overview






Untreated Childhood Acute Lymphoblastic Leukemia






Childhood Acute Lymphoblastic Leukemia in Remission






Postinduction Treatment for Childhood Acute Lymphoblastic Leukemia Subgroups






Recurrent Childhood Acute Lymphoblastic Leukemia






Get More Information From NCI







Changes to this Summary (05/30/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Changes to this Summary (05/30/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added Shah et al. as reference 5.

Cellular Classification and Prognostic Variables

Added text to state that the European Organization for Research and Treatment of Cancer reported no adverse prognostic significance for overt testicular involvement at diagnosis (cited Sirvent et al. as reference 10).

Added text to state that high leukemia cell expression of the gene for interleukin-15 is associated with an increased likelihood of CNS3 status at diagnosis and also may predict for a higher rate of CNS relapse in patients who present with CNS1 status at diagnosis (cited Cario et al. as reference 38).

Added Zhou et al. as reference 113.

Added text to state that clinical trials of three major United States pediatric ALL groups use MRD measurements to determine post-induction treatment.

Postinduction Treatment for Childhood Acute Lymphoblastic Leukemia Subgroups

Added Silverman et al. as reference 9.

Added Tomizawa et al. as reference 10.

Recurrent Childhood Acute Lymphoblastic Leukemia

Added text to state that some evidence that matched unrelated donor transplantation may yield a lower relapse rate (cited Gassas et al. as reference 44).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov